Targeting Mitochondrial Metabolism Shows Promise in Pancreatic Cancer

Researchers report promising results from a phase I trial evaluating CPI-613, which targets mitochondrial metabolism, in combination with modified FOLFIRINOX chemotherapy for the treatment of metastatic pancreatic cancer.

They say: “This study provides encouraging evidence for a novel, potentially effective combination chemotherapy regimen […] that was safe and well tolerated in patients with metastatic pancreatic cancer.” Read more . . .

Conversation

Join our community Sign up for updates from Let’s Win!

Terms & Conditions • Privacy Policy

Let’s Win! Pancreatic Cancer is an online community for sharing information about innovative, science-based treatments for pancreatic cancer. Please note that this information is not intended to be a substitute for professional medical opinion, advice, or diagnosis. We encourage you to use this information to begin a dialogue with your physician about the treatment plan that is right for you.